Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building...
Research Including Patients from Quebec Demonstrated Significant Impact of Genomic Health's Oncotype DX® in Personalizing Cancer Treatments REDWOOD CITY, CA, March 30, 2017 /CNW/ - Genomic Health,...
New England Journal of Medicine publishes positive results from one of the largest-ever adjuvant breast cancer trials TORONTO, Sept. 28, 2015 /CNW/ - Genomic Health today announced the presentation...
Largest Genomic Study in DCIS Shows Genomic Health's Oncotype DX Predicts Local Recurrence, Helps Personalise Treatment of Stage 0 Breast Cancer TORONTO, Aug. 20, 2015 /CNW/ - Genomic Health, Inc....
Genomic Health's Test Now Available to Eligible Patients in the Province VANCOUVER, April 22, 2014 /CNW/ - The Oncotype DX® breast cancer test, the only genomic test to predict chemotherapy benefit...
Genomic Health's Oncotype DX test increasingly used to help predict chemotherapy benefit and risk of recurrence in early-stage breast cancer patients MONTREAL, March 20, 2012 /CNW Telbec/ - More than ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.